Sébastien Richard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sébastien Richard has a total of 596 co-authors. Here are the top co-authors by number of shared publications:
- Gaultier Marnat
Department of Neuroradiology, Bordeaux University Hospital, Bordeaux, France
26 shared publications - Benjamin Gory
Department of Diagnostic and Therapeutic Neuroradiology, CHRU-Nancy, Nancy, France
20 shared publications Igor Sibon
Department of Neurology (I.S.), Hôpital Pellegrin, Bordeaux, France
18 shared publicationsGioia Mione
17 shared publicationsCaroline Arquizan
Department of Neurology (C.A.), Hôpital Gui de Chauliac, Montpellier, France
15 shared publicationsBenjamin Gory
Department of Neuroradiology (B.G.), Hôpital Central, Nancy, France
14 shared publications
Latest Publications
- 1 October 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (10) , 3159-3169
Intraarterial Thrombolysis: Past, Present, Future
Suboptimal clinical outcomes are common after ischemic stroke with large vessel occlusion despite current reperfusion treatment with intravenous thrombolysis and mechanical thrombectomy. Targeting residual distal arterial and microvascular occlusions with intraarterial thrombolysis has recently gained substantial interest as an adjunct to improve cerebral tissue perfusion. While recent trials provide promise in selected patients with anterior-circulation stroke, further high-quality, large-scale studies and pooled individual-patient analyses are needed. This review summarizes the evolving role of intraarterial thrombolysis over the past 3 decades and projects potential developments.
- 1 October 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (10) , 3159-3169
Intraarterial Thrombolysis: Past, Present, Future
Suboptimal clinical outcomes are common after ischemic stroke with large vessel occlusion despite current reperfusion treatment with intravenous thrombolysis and mechanical thrombectomy. Targeting residual distal arterial and microvascular occlusions with intraarterial thrombolysis has recently gained substantial interest as an adjunct to improve cerebral tissue perfusion. While recent trials provide promise in selected patients with anterior-circulation stroke, further high-quality, large-scale studies and pooled individual-patient analyses are needed. This review summarizes the evolving role of intraarterial thrombolysis over the past 3 decades and projects potential developments.
- 23 June 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (12) , e218125
IV Thrombolysis Before Thrombectomy in Carotid Artery Dissection–Related Large-Vessel Occlusion
The benefit of IV thrombolysis (IVT) before thrombectomy in patients with anterior-circulation large-vessel occlusion (LVO) due to carotid artery dissection (CAD) remains uncertain. We aimed to evaluate the safety and efficacy of IVT in this specific population in clinical practice. This study included patients from the Carotid Dissection Thrombectomy vs Medical Treatment collaboration and the Endovascular Treatment in Ischemic Stroke registry with anterior-circulation LVO due to CAD who were treated with thrombectomy, with or without prior IVT. The coprimary outcomes were favorable functional outcome at 3 months (modified Rankin Scale 0-2) and successful reperfusion (thrombolysis in cerebral infarction score ≥2b). The safety end point was symptomatic intracranial hemorrhage (sICH). Inverse probability of treatment weighting was applied to adjust for baseline imbalances, and weighted Poisson regression models were used to estimate adjusted risk ratios (aRRs). A total of 1,091 patients (mean age 53.0 years, 74.0% men) were included, of whom 571 patients received IVT prior thrombectomy and 520 underwent thrombectomy only. IVT before thrombectomy was associated with a higher likelihood of favorable functional outcome (aRR 1.16, 95% CI 1.03-1.30, p = 0.013) and successful reperfusion (aRR 1.34, 95% CI 1.18-1.53, p < 0.001). No association was observed with sICH (aRR 0.69, 95% CI 0.41-1.16, p = 0.161). Subgroup analyses showed that the functional benefit of IVT was pronounced in patients with higher admission NIH Stroke Scale scores (p interaction = 0.039). IVT prior thrombectomy was associated with improved functional outcome and higher reperfusion success in patients with anterior-circulation LVO due to CAD, without an increase in sICH. The association with functional outcome was largely driven by patients presenting with higher admission stroke severity. This study provides Class III evidence that IVT before thrombectomy was associated with improved functional outcome and higher reperfusion success in patients with anterior-circulation LVO due to CAD, without an increase in sICH.
- 23 June 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (12) , e218125
IV Thrombolysis Before Thrombectomy in Carotid Artery Dissection–Related Large-Vessel Occlusion
The benefit of IV thrombolysis (IVT) before thrombectomy in patients with anterior-circulation large-vessel occlusion (LVO) due to carotid artery dissection (CAD) remains uncertain. We aimed to evaluate the safety and efficacy of IVT in this specific population in clinical practice. This study included patients from the Carotid Dissection Thrombectomy vs Medical Treatment collaboration and the Endovascular Treatment in Ischemic Stroke registry with anterior-circulation LVO due to CAD who were treated with thrombectomy, with or without prior IVT. The coprimary outcomes were favorable functional outcome at 3 months (modified Rankin Scale 0-2) and successful reperfusion (thrombolysis in cerebral infarction score ≥2b). The safety end point was symptomatic intracranial hemorrhage (sICH). Inverse probability of treatment weighting was applied to adjust for baseline imbalances, and weighted Poisson regression models were used to estimate adjusted risk ratios (aRRs). A total of 1,091 patients (mean age 53.0 years, 74.0% men) were included, of whom 571 patients received IVT prior thrombectomy and 520 underwent thrombectomy only. IVT before thrombectomy was associated with a higher likelihood of favorable functional outcome (aRR 1.16, 95% CI 1.03-1.30, p = 0.013) and successful reperfusion (aRR 1.34, 95% CI 1.18-1.53, p < 0.001). No association was observed with sICH (aRR 0.69, 95% CI 0.41-1.16, p = 0.161). Subgroup analyses showed that the functional benefit of IVT was pronounced in patients with higher admission NIH Stroke Scale scores (p interaction = 0.039). IVT prior thrombectomy was associated with improved functional outcome and higher reperfusion success in patients with anterior-circulation LVO due to CAD, without an increase in sICH. The association with functional outcome was largely driven by patients presenting with higher admission stroke severity. This study provides Class III evidence that IVT before thrombectomy was associated with improved functional outcome and higher reperfusion success in patients with anterior-circulation LVO due to CAD, without an increase in sICH.
- 1 June 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (6) , 1504-1512
Endovascular Thrombectomy in Patients With Largest Baseline Infarcts (ASPECTS 0–2): An Ancillary Analysis of the LASTE Trial
BACKGROUND: Endovascular thrombectomy (EVT) has demonstrated benefits in patients with ischemic stroke and large-vessel occlusions, but its efficacy and safety in patients with the largest baseline infarcts (Alberta Stroke Program Early Computed Tomography Score [ASPECTS] 0–2), remain controversial. This study aimed to evaluate the efficacy and safety of EVT in early presenting patients with ASPECTS 0 to 2 compared with medical care alone. METHODS: This post hoc analysis of the multicenter, randomized LASTE trial ([Large Stroke Therapy Evaluation]; patients ≤80 years, ASPECTS 0–5, proximal anterior circulation large-vessel occlusion, randomization within 6.5 hours of last known well) evaluated the subgroup with ASPECTS 0 to 2, representing those with large baseline infarcts without an upper size limit, randomized to receive EVT plus medical care or medical care alone. Primary outcomes included the distribution of the modified Rankin Scale score at 90 days. Secondary outcomes included mortality, infarct volume growth at 24 hours, the incidence of symptomatic intracranial hemorrhage and modified Rankin Scale score at 180 days. The LASTE trial was conducted and reported in accordance with the CONSORT guidelines (Consolidated Standards of Reporting Trials). RESULTS: Median age was 72 years and 55.8% were women. Among the 181 patients with ASPECTS 0 to 2 (median core volume 156 mL [25th–75th percentiles, 121–204 mL]), at 90 days after randomization, EVT improved functional outcomes (generalized odds ratio, 1.81 [95% CI, 1.32–2.47]) and reduced mortality (38.4% versus 59.6%; relative risk, 0.64 [95% CI, 0.47–0.89]), which translated predominantly into an increase in the proportion of modified Rankin Scale score of 0 to 3 in the EVT group (31.4% versus 8.5%; relative risk, 3.69 [95% CI, 1.77–7.68]). A significant reduction in infarct growth volume was observed in the EVT group compared with medical care (mean difference, −70.3 mL [95% CI, −94.2 to −46.3]). Rates of symptomatic intracranial hemorrhage were 12.9% versus 4.5%, respectively (relative risk, 2.85 [95% CI, 0.94–8.60]). CONCLUSIONS: EVT improves functional outcomes and reduces mortality in patients with ASPECTS 0 to 2. These findings support the concept that in patients aged <80 years presenting within early time window (6.5 hours) with unlimitedly large infarct (predominantly selected using magnetic resonance imaging), the infarct size in isolation should not be used to disqualify patients from endovascular treatment. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03811769.
- 1 June 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (6) , 1504-1512
Endovascular Thrombectomy in Patients With Largest Baseline Infarcts (ASPECTS 0–2): An Ancillary Analysis of the LASTE Trial
BACKGROUND: Endovascular thrombectomy (EVT) has demonstrated benefits in patients with ischemic stroke and large-vessel occlusions, but its efficacy and safety in patients with the largest baseline infarcts (Alberta Stroke Program Early Computed Tomography Score [ASPECTS] 0–2), remain controversial. This study aimed to evaluate the efficacy and safety of EVT in early presenting patients with ASPECTS 0 to 2 compared with medical care alone. METHODS: This post hoc analysis of the multicenter, randomized LASTE trial ([Large Stroke Therapy Evaluation]; patients ≤80 years, ASPECTS 0–5, proximal anterior circulation large-vessel occlusion, randomization within 6.5 hours of last known well) evaluated the subgroup with ASPECTS 0 to 2, representing those with large baseline infarcts without an upper size limit, randomized to receive EVT plus medical care or medical care alone. Primary outcomes included the distribution of the modified Rankin Scale score at 90 days. Secondary outcomes included mortality, infarct volume growth at 24 hours, the incidence of symptomatic intracranial hemorrhage and modified Rankin Scale score at 180 days. The LASTE trial was conducted and reported in accordance with the CONSORT guidelines (Consolidated Standards of Reporting Trials). RESULTS: Median age was 72 years and 55.8% were women. Among the 181 patients with ASPECTS 0 to 2 (median core volume 156 mL [25th–75th percentiles, 121–204 mL]), at 90 days after randomization, EVT improved functional outcomes (generalized odds ratio, 1.81 [95% CI, 1.32–2.47]) and reduced mortality (38.4% versus 59.6%; relative risk, 0.64 [95% CI, 0.47–0.89]), which translated predominantly into an increase in the proportion of modified Rankin Scale score of 0 to 3 in the EVT group (31.4% versus 8.5%; relative risk, 3.69 [95% CI, 1.77–7.68]). A significant reduction in infarct growth volume was observed in the EVT group compared with medical care (mean difference, −70.3 mL [95% CI, −94.2 to −46.3]). Rates of symptomatic intracranial hemorrhage were 12.9% versus 4.5%, respectively (relative risk, 2.85 [95% CI, 0.94–8.60]). CONCLUSIONS: EVT improves functional outcomes and reduces mortality in patients with ASPECTS 0 to 2. These findings support the concept that in patients aged <80 years presenting within early time window (6.5 hours) with unlimitedly large infarct (predominantly selected using magnetic resonance imaging), the infarct size in isolation should not be used to disqualify patients from endovascular treatment. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03811769.
- Open Access
- 1 May 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (5) , 1116-1125
Glenzocimab Efficacy and Safety Added to Intravenous Thrombolysis With or Without Mechanical Thrombectomy in Patients With Acute Ischemic Stroke—ACTISAVE: A Prospective, Randomized, Double-Blind Study
BACKGROUND: Glenzocimab, a platelet glycoprotein VI antagonist, is a novel agent that inhibits platelet activation and aggregation. Its safety was demonstrated in the ACTIMIS trial (Acute Ischemic Stroke Interventional Study; URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03803007) for patients with stroke receiving thrombolysis, with or without mechanical thrombectomy, and results suggested a reduction in intracranial hemorrhages and mortality. The ACTISAVE trial was designed as a confirmatory study to evaluate the efficacy and safety of glenzocimab in acute ischemic stroke. METHODS: ACTISAVE (Acute Ischemic Stroke Study Evaluating Glenzocimab Used as Add-On Therapy Versus Placebo) was an international, randomized, double-blind, placebo-controlled phase 2/3 study in patients with stroke, treated by thrombolysis within 4.5 hours of symptoms onset with or without mechanical thrombectomy. The study was conducted at 54 primary and comprehensive stroke centers located in 10 countries. Patients were randomized 1:1 to glenzocimab (1000 mg-IV) or placebo. The primary outcome was the modified Rankin Scale (mRS) score of 4 to 6 at day 90. Key secondary outcome was the mRS score of 0 to 2 at day 90. Mortality, mRS shift, National Institutes of Health Stroke Scale score, quality of life, and safety outcomes were assessed. RESULTS: Between September 2021 and October 2023, 438 patients were randomized, 421 treated, and included as randomized in the primary analysis set. Median age was 73 (63–80) years, and 43% were female. Thrombolysis was performed 2.3 hours (median) after symptom onset and followed by mechanical thrombectomy in 36% of patients. The assigned treatment began a median of 1.2 (interquartile range, 0.8–1.6) hours after thrombolysis initiation. Prethrombolysis National Institutes of Health Stroke Scale score median was 9 (6–15). At day 90, there was no statistically significant difference in the primary outcome between the treatment groups: the incidence of poor outcome (mRS score 4–6 versus 0–3) was 21.6% in the glenzocimab group compared with 15.3% placebo group (odds ratio, 1.51 [95% CI, 0.90–2.54]; P =0.120). No statistically significant difference in secondary outcomes was observed. There were no major safety signals with any intracerebral hemorrhage occurring respectively in 60 (28.6%) and 63 (29.9%) patients in glenzocimab and placebo arms. CONCLUSIONS: ACTISAVE failed to confirm a beneficial effect of glenzocimab on mRS in patients with acute ischemic stroke treated by thrombolysis. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05070260.
- 1 May 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (5) , 1116-1125
Open AccessGlenzocimab Efficacy and Safety Added to Intravenous Thrombolysis With or Without Mechanical Thrombectomy in Patients With Acute Ischemic Stroke—ACTISAVE: A Prospective, Randomized, Double-Blind Study
BACKGROUND: Glenzocimab, a platelet glycoprotein VI antagonist, is a novel agent that inhibits platelet activation and aggregation. Its safety was demonstrated in the ACTIMIS trial (Acute Ischemic Stroke Interventional Study; URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03803007) for patients with stroke receiving thrombolysis, with or without mechanical thrombectomy, and results suggested a reduction in intracranial hemorrhages and mortality. The ACTISAVE trial was designed as a confirmatory study to evaluate the efficacy and safety of glenzocimab in acute ischemic stroke. METHODS: ACTISAVE (Acute Ischemic Stroke Study Evaluating Glenzocimab Used as Add-On Therapy Versus Placebo) was an international, randomized, double-blind, placebo-controlled phase 2/3 study in patients with stroke, treated by thrombolysis within 4.5 hours of symptoms onset with or without mechanical thrombectomy. The study was conducted at 54 primary and comprehensive stroke centers located in 10 countries. Patients were randomized 1:1 to glenzocimab (1000 mg-IV) or placebo. The primary outcome was the modified Rankin Scale (mRS) score of 4 to 6 at day 90. Key secondary outcome was the mRS score of 0 to 2 at day 90. Mortality, mRS shift, National Institutes of Health Stroke Scale score, quality of life, and safety outcomes were assessed. RESULTS: Between September 2021 and October 2023, 438 patients were randomized, 421 treated, and included as randomized in the primary analysis set. Median age was 73 (63–80) years, and 43% were female. Thrombolysis was performed 2.3 hours (median) after symptom onset and followed by mechanical thrombectomy in 36% of patients. The assigned treatment began a median of 1.2 (interquartile range, 0.8–1.6) hours after thrombolysis initiation. Prethrombolysis National Institutes of Health Stroke Scale score median was 9 (6–15). At day 90, there was no statistically significant difference in the primary outcome between the treatment groups: the incidence of poor outcome (mRS score 4–6 versus 0–3) was 21.6% in the glenzocimab group compared with 15.3% placebo group (odds ratio, 1.51 [95% CI, 0.90–2.54]; P =0.120). No statistically significant difference in secondary outcomes was observed. There were no major safety signals with any intracerebral hemorrhage occurring respectively in 60 (28.6%) and 63 (29.9%) patients in glenzocimab and placebo arms. CONCLUSIONS: ACTISAVE failed to confirm a beneficial effect of glenzocimab on mRS in patients with acute ischemic stroke treated by thrombolysis. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05070260.
- 30 March 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Explorations des fonctions plaquettaires exposées à l'aspirine au décours de l'accident vasculaire cérébral ischémique
L'aspirine est l'anti-plaquettaire le plus largement prescrit à la phase aiguë de l'accident vasculaire cérébral (AVC) ischémique. Cependant, la survenue de récidives, malgré cette prescription, est fréquente. La description de l'effet de l'aspirine sur l'activité plaquettaire durant cette phase n'a jamais été réalisée. Elle pourrait mettre en évidence une moindre réponse plaquettaire et aider à établir de nouvelles stratégies thérapeutiques. Cinquante patients, ont reçu par voie orale 300 mg d'aspirine, suite à un AVC ischémique. Ensuite, des prélèvements sanguins ont été réalisés : entre 2 et 3 heures (T1), entre 23 et 24 heures (T2) après la prise d'aspirine et, pour des patients déjà traités quotidiennement par une dose inférieure, avant la prise d'aspirine (T0). Les concentrations sériques de thromboxane (TX) B2 ont été mesurées, ainsi que les agrégations induites par l'acide arachidonique, par le collagène à la concentration de 2µg/L (Col2) et 20 µg/L (Col20). Afin de diminuer l'effet des variations de condition d'expérience, les résultats pour Col2 ont été rapportés à ceux pour Col20 (Col2/20). Tous les patients ont présenté une réponse à l?aspirine visible à T1 avec de plus, des concentrations de TXB2 abaissées en comparaison à T0. Il existe une récupération de l'activité plaquettaire à T2 comparée à T1, montrée par les concentrations de TXB2 et le rapport Col2/20. La dose orale de 300 mg d'aspirine, donnée à la phase aiguë de l'AVC, entraîne une inhibition plaquettaire, mais avec une récupération visible sur 24 heures. Pour les patients déjà traités quotidiennement par une dose inférieure, elle permet de compléter l'inhibition de la voie TXA2 dépendante
- 30 March 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Explorations des fonctions plaquettaires exposées à l'aspirine au décours de l'accident vasculaire cérébral ischémique
L'aspirine est l'anti-plaquettaire le plus largement prescrit à la phase aiguë de l'accident vasculaire cérébral (AVC) ischémique. Cependant, la survenue de récidives, malgré cette prescription, est fréquente. La description de l'effet de l'aspirine sur l'activité plaquettaire durant cette phase n'a jamais été réalisée. Elle pourrait mettre en évidence une moindre réponse plaquettaire et aider à établir de nouvelles stratégies thérapeutiques. Cinquante patients, ont reçu par voie orale 300 mg d'aspirine, suite à un AVC ischémique. Ensuite, des prélèvements sanguins ont été réalisés : entre 2 et 3 heures (T1), entre 23 et 24 heures (T2) après la prise d'aspirine et, pour des patients déjà traités quotidiennement par une dose inférieure, avant la prise d'aspirine (T0). Les concentrations sériques de thromboxane (TX) B2 ont été mesurées, ainsi que les agrégations induites par l'acide arachidonique, par le collagène à la concentration de 2µg/L (Col2) et 20 µg/L (Col20). Afin de diminuer l'effet des variations de condition d'expérience, les résultats pour Col2 ont été rapportés à ceux pour Col20 (Col2/20). Tous les patients ont présenté une réponse à l?aspirine visible à T1 avec de plus, des concentrations de TXB2 abaissées en comparaison à T0. Il existe une récupération de l'activité plaquettaire à T2 comparée à T1, montrée par les concentrations de TXB2 et le rapport Col2/20. La dose orale de 300 mg d'aspirine, donnée à la phase aiguë de l'AVC, entraîne une inhibition plaquettaire, mais avec une récupération visible sur 24 heures. Pour les patients déjà traités quotidiennement par une dose inférieure, elle permet de compléter l'inhibition de la voie TXA2 dépendante
- 24 March 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (6) , e214702
IV Tenecteplase Before Thrombectomy Compared With Thrombectomy Alone in Patients With Stroke Due to a Large Vessel Occlusion
The benefit of IV thrombolysis (IVT) with alteplase before endovascular thrombectomy (EVT) compared with EVT alone has been shown to be limited and time dependent. Data on tenecteplase, its recommended alternative, are limited. We aimed to assess the efficacy and safety of IVT with tenecteplase plus mechanical thrombectomy (TNK + EVT) compared with EVT in patients with large vessel occlusion stroke and determine whether its potential benefit decreases with treatment time. We conducted a retrospective pooled analysis of 2 nationwide, real-world registries of patients with anterior circulation large vessel occlusion stroke within 4.5 hours of known symptom onset and with no contraindication to thrombolysis, treated with TNK + EVT (TETRIS) or EVT (ETIS). The efficacy outcome was the 3-month modified Rankin Scale (mRS) score, analyzed in ordinal and dichotomized (mRS score ≤2) approaches. We used propensity score-weighted logistic regression to assess associations between treatment groups and outcomes of interest. Among 1,890 patients who were analyzed (TNK + EVT: n = 798; EVT: n = 1,092; median age 73 years [interquartile range 61-82]; 49.6% women), the median expected onset-to-thrombolysis time was 146 minutes [interquartile range 119-180]. More than half of patients (n = 1,063; 56.2%) were admitted first to a primary stroke center. All baseline characteristics were balanced between treatment groups after overlap weighting. Overall, TNK + EVT was associated with better 3-month functional outcome over the full mRS (weighted common odds ratio [OR] 1.53 [95% CI 1.29-1.82]; p < 0.001) and regarding functional independence (propensity score overlap weighting [PSOW]-OR 1.50 [95% CI 1.23-1.84]; p < 0.001). This benefit did not differ statistically between patients admitted first to a primary or comprehensive stroke center (p-interaction = 0.12). There was no significant effect of the expected onset-to-thrombolysis time on the association between TNK + EVT and better functional outcome (p-interaction = 0.11). There were no significant differences in parenchymal hematoma (PSOW-OR 1.29 [95% CI 0.94-1.79]; p = 0.12) and symptomatic intracerebral hemorrhage (PSOW-OR 1.13 [95% CI 0.69-1.86]; p = 0.61) rates. Among patients treated within 4.5 hours of symptom onset, TNK + EVT was associated with better functional outcome than EVT, without safety concerns. This benefit does not seem to be time dependent. These findings support the routine use of tenecteplase before EVT in the early time window. This study provides Class II evidence that, in patients with stroke due to anterior circulation large vessel occlusion, IV tenecteplase plus thrombectomy is associated with better functional outcomes at 3 months compared with thrombectomy alone. NCT03776877 (ETIS registry) and NCT05534360 (TETRIS registry).
- 24 March 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (6) , e214702
IV Tenecteplase Before Thrombectomy Compared With Thrombectomy Alone in Patients With Stroke Due to a Large Vessel Occlusion
The benefit of IV thrombolysis (IVT) with alteplase before endovascular thrombectomy (EVT) compared with EVT alone has been shown to be limited and time dependent. Data on tenecteplase, its recommended alternative, are limited. We aimed to assess the efficacy and safety of IVT with tenecteplase plus mechanical thrombectomy (TNK + EVT) compared with EVT in patients with large vessel occlusion stroke and determine whether its potential benefit decreases with treatment time. We conducted a retrospective pooled analysis of 2 nationwide, real-world registries of patients with anterior circulation large vessel occlusion stroke within 4.5 hours of known symptom onset and with no contraindication to thrombolysis, treated with TNK + EVT (TETRIS) or EVT (ETIS). The efficacy outcome was the 3-month modified Rankin Scale (mRS) score, analyzed in ordinal and dichotomized (mRS score ≤2) approaches. We used propensity score-weighted logistic regression to assess associations between treatment groups and outcomes of interest. Among 1,890 patients who were analyzed (TNK + EVT: n = 798; EVT: n = 1,092; median age 73 years [interquartile range 61-82]; 49.6% women), the median expected onset-to-thrombolysis time was 146 minutes [interquartile range 119-180]. More than half of patients (n = 1,063; 56.2%) were admitted first to a primary stroke center. All baseline characteristics were balanced between treatment groups after overlap weighting. Overall, TNK + EVT was associated with better 3-month functional outcome over the full mRS (weighted common odds ratio [OR] 1.53 [95% CI 1.29-1.82]; p < 0.001) and regarding functional independence (propensity score overlap weighting [PSOW]-OR 1.50 [95% CI 1.23-1.84]; p < 0.001). This benefit did not differ statistically between patients admitted first to a primary or comprehensive stroke center (p-interaction = 0.12). There was no significant effect of the expected onset-to-thrombolysis time on the association between TNK + EVT and better functional outcome (p-interaction = 0.11). There were no significant differences in parenchymal hematoma (PSOW-OR 1.29 [95% CI 0.94-1.79]; p = 0.12) and symptomatic intracerebral hemorrhage (PSOW-OR 1.13 [95% CI 0.69-1.86]; p = 0.61) rates. Among patients treated within 4.5 hours of symptom onset, TNK + EVT was associated with better functional outcome than EVT, without safety concerns. This benefit does not seem to be time dependent. These findings support the routine use of tenecteplase before EVT in the early time window. This study provides Class II evidence that, in patients with stroke due to anterior circulation large vessel occlusion, IV tenecteplase plus thrombectomy is associated with better functional outcomes at 3 months compared with thrombectomy alone. NCT03776877 (ETIS registry) and NCT05534360 (TETRIS registry).
- 6 March 2026
- Published by BMJ in Journal of NeuroInterventional Surgery
Efficacy and safety of bridging therapy and thrombectomy alone in patients with large infarcts of unrestricted size: LASTE trial post hoc analysis
Background: Endovascular thrombectomy (EVT) is now the standard treatment for patients with large cerebral infarcts. However, the benefit of intravenous thrombolysis before EVT (IVT+EVT) in this setting is uncertain. Methods: We conducted a post hoc analysis of the Large Stroke Therapy Evaluation (LASTE) trial, which randomized patients with large infarcts (Alberta stroke program early CT score (ASPECTS) ≤5) to EVT plus medical care or medical care alone. Among those assigned to EVT, patients were divided into two groups: IVT+EVT and EVT alone. The main outcome was the shift analysis of the 3 month modified Rankin Scale (mRS) score. Safety outcomes included parenchymal hemorrhage (PH) and symptomatic intracranial hemorrhage (sICH). Results: Among 159 patients allocated to EVT, 55 received IVT+EVT and 104 EVT alone. Patients in the IVT+EVT group had lower National Institutes of Health Stroke Scale (NIHSS) scores (median 19 (IQR 17–22) vs 22, (19–24) p=0.003), were less often anticoagulated (3.6% vs 27.9%, p<0.001) and shorter onset-to-imaging time (median 148 (91-280) vs 200 (123-311); P=0.024). Both groups had similar rates of ASPECTS 0–2 (50.9% vs 55.8%; P=0.56). There was no significant difference in 3 month functional outcome between IVT+EVT and EVT alone (generalized OR 1.22 (95% CI 0.85 to 1.74); P=0.28) or sICH (RR 1.72 (95% CI 0.65 to 4.48); P=0.27). Pre-EVT recanalization was higher in the IVT+EVT group (RR 15.1 (95% CI 1.9 to 117.9); P<0.001). Mortality rates did not differ significantly. Discussion: In patients with very large infarcts, IVT+EVT was not associated with better functional outcome than EVT alone, despite higher pre-EVT recanalization rates. Safety outcomes were comparable. Randomized trials are warranted to clarify the role of IVT in this high-risk population. Trial registration number: NCT03811769 .
- 6 March 2026
- Published by BMJ in Journal of NeuroInterventional Surgery
Efficacy and safety of bridging therapy and thrombectomy alone in patients with large infarcts of unrestricted size: LASTE trial post hoc analysis
Background: Endovascular thrombectomy (EVT) is now the standard treatment for patients with large cerebral infarcts. However, the benefit of intravenous thrombolysis before EVT (IVT+EVT) in this setting is uncertain. Methods: We conducted a post hoc analysis of the Large Stroke Therapy Evaluation (LASTE) trial, which randomized patients with large infarcts (Alberta stroke program early CT score (ASPECTS) ≤5) to EVT plus medical care or medical care alone. Among those assigned to EVT, patients were divided into two groups: IVT+EVT and EVT alone. The main outcome was the shift analysis of the 3 month modified Rankin Scale (mRS) score. Safety outcomes included parenchymal hemorrhage (PH) and symptomatic intracranial hemorrhage (sICH). Results: Among 159 patients allocated to EVT, 55 received IVT+EVT and 104 EVT alone. Patients in the IVT+EVT group had lower National Institutes of Health Stroke Scale (NIHSS) scores (median 19 (IQR 17–22) vs 22, (19–24) p=0.003), were less often anticoagulated (3.6% vs 27.9%, p<0.001) and shorter onset-to-imaging time (median 148 (91-280) vs 200 (123-311); P=0.024). Both groups had similar rates of ASPECTS 0–2 (50.9% vs 55.8%; P=0.56). There was no significant difference in 3 month functional outcome between IVT+EVT and EVT alone (generalized OR 1.22 (95% CI 0.85 to 1.74); P=0.28) or sICH (RR 1.72 (95% CI 0.65 to 4.48); P=0.27). Pre-EVT recanalization was higher in the IVT+EVT group (RR 15.1 (95% CI 1.9 to 117.9); P<0.001). Mortality rates did not differ significantly. Discussion: In patients with very large infarcts, IVT+EVT was not associated with better functional outcome than EVT alone, despite higher pre-EVT recanalization rates. Safety outcomes were comparable. Randomized trials are warranted to clarify the role of IVT in this high-risk population. Trial registration number: NCT03811769 .
- 10 February 2026
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 47 (7) , ajnr.A9204-1852
Influence of the anesthetic regimen during the endovascular treatment of intracranial proximal occlusions with large infarct core: a post-hoc analysis of the LASTE trial data
The optimal anesthetic regimen for the endovascular treatment (EVT) of stroke due to large vessel occlusion remains unclear. Patients with large infarct core on initial imaging constitute a specific subpopulation. The aim of this study was to investigate the impact of the anesthesia type during EVT on outcomes in this subpopulation. Data were extracted from the multicenter, randomized, controlled LASTE trial (n = 30 centers in France and Spain) that compared EVT plus best medical treatment versus best medical treatment alone in patients with large infarct core (ASPECTS = 0-5). In this post-hoc analysis, only patients who underwent EVT were included. Two study groups were defined: general anesthesia (GA), and conscious sedation and/or local anesthesia (CS-LA). The primary endpoint was the functional outcome, assessed with the modified Rankin Scale (mRS) at 3 months. Secondary endpoints included early neurological status, infarct extension at day 1, symptomatic intracranial hemorrhage, and mortality. Endpoints were investigated using univariate and multivariate analyses adjusted for pre-specified confounders. For this post-hoc analysis, 159 patients were included: 45 in the GA group and 114 in the CS-LA group. The functional outcome at 3 months was not different between groups: median mRS score = 5 (IQR: 3-6) in the GA and 4 (IQR: 3-6) in the CS-LA group (adjusted OR = 0.78; 95% CI 0.52 - 1.18). However, in the GA group, the National Institutes of Health Stroke Scale score significantly worsened between admission and day 1 [mean difference= -3.8 (-6.6 to -1.0), p=0.007], infarct volume extension was more severe [mean difference: -26.5 ml (-50.2 to -2.9), p=0.028], and parenchymal hematoma was more frequently detected. Between-group differences in early neurological improvement, symptomatic intracranial hemorrhage, and mortality were not significant. In this post-hoc analysis of the LASTE trial data, we detected potential signals of a GA detrimental effect in patients with large infarct core on baseline imaging. Larger studies are necessary to confirm this finding.
- 10 February 2026
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 47 (7) , ajnr.A9204-1852
Influence of the anesthetic regimen during the endovascular treatment of intracranial proximal occlusions with large infarct core: a post-hoc analysis of the LASTE trial data
The optimal anesthetic regimen for the endovascular treatment (EVT) of stroke due to large vessel occlusion remains unclear. Patients with large infarct core on initial imaging constitute a specific subpopulation. The aim of this study was to investigate the impact of the anesthesia type during EVT on outcomes in this subpopulation. Data were extracted from the multicenter, randomized, controlled LASTE trial (n = 30 centers in France and Spain) that compared EVT plus best medical treatment versus best medical treatment alone in patients with large infarct core (ASPECTS = 0-5). In this post-hoc analysis, only patients who underwent EVT were included. Two study groups were defined: general anesthesia (GA), and conscious sedation and/or local anesthesia (CS-LA). The primary endpoint was the functional outcome, assessed with the modified Rankin Scale (mRS) at 3 months. Secondary endpoints included early neurological status, infarct extension at day 1, symptomatic intracranial hemorrhage, and mortality. Endpoints were investigated using univariate and multivariate analyses adjusted for pre-specified confounders. For this post-hoc analysis, 159 patients were included: 45 in the GA group and 114 in the CS-LA group. The functional outcome at 3 months was not different between groups: median mRS score = 5 (IQR: 3-6) in the GA and 4 (IQR: 3-6) in the CS-LA group (adjusted OR = 0.78; 95% CI 0.52 - 1.18). However, in the GA group, the National Institutes of Health Stroke Scale score significantly worsened between admission and day 1 [mean difference= -3.8 (-6.6 to -1.0), p=0.007], infarct volume extension was more severe [mean difference: -26.5 ml (-50.2 to -2.9), p=0.028], and parenchymal hematoma was more frequently detected. Between-group differences in early neurological improvement, symptomatic intracranial hemorrhage, and mortality were not significant. In this post-hoc analysis of the LASTE trial data, we detected potential signals of a GA detrimental effect in patients with large infarct core on baseline imaging. Larger studies are necessary to confirm this finding.
- 27 August 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (6) , 1539-1544
Glenzocimab for reperfusion in the setting of endovascular therapy for brain infarction: GREEN study
Background Glenzocimab is a humanized fragment of a monoclonal antibody directed against the human platelet glycoprotein VI, which has shown promising features, including thrombus growth inhibition and minimal bleeding risk. The first inpatient study suggested the benefit of glenzocimab with alteplase in subgroups of patients with acute ischemic stroke (AIS) receiving endovascular treatment (EVT), with increased reperfusion rates and decreased risk of symptomatic hemorrhagic transformation. The objective of the GREEN (Glenzocimab for REperfusion in the setting of Endovascular therapy for brain infarctioN) study is to evaluate the efficacy of glenzocimab with EVT compared with EVT plus placebo, with or without intravenous thrombolysis (IVT), on functional outcome. Methods GREEN is a multicenter, randomized, double blind, placebo controlled study. Participants presenting with AIS and a large vessel occlusion of the anterior circulation (intracranial internal carotid artery or middle cerebral artery, or both), with symptoms onset within 24 hours, will be randomized to one of two groups: intravenous glenzocimab 1000 mg with standard of care (SoC-EVT±IVT) or SoC (EVT±IVT) plus placebo. The main primary efficacy endpoint is functional outcome (assessed by the modified Rankin Scale score) at 90 days. Conclusion This is the first randomized trial evaluating the efficacy of glenzocimab with EVT. This prospective trial aims to determine whether glenzocimab with EVT improves functional outcome. Trial registration ClinicalTrials.gov NCT05559398
- 27 August 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (6) , 1539-1544
Glenzocimab for reperfusion in the setting of endovascular therapy for brain infarction: GREEN study
Background Glenzocimab is a humanized fragment of a monoclonal antibody directed against the human platelet glycoprotein VI, which has shown promising features, including thrombus growth inhibition and minimal bleeding risk. The first inpatient study suggested the benefit of glenzocimab with alteplase in subgroups of patients with acute ischemic stroke (AIS) receiving endovascular treatment (EVT), with increased reperfusion rates and decreased risk of symptomatic hemorrhagic transformation. The objective of the GREEN (Glenzocimab for REperfusion in the setting of Endovascular therapy for brain infarctioN) study is to evaluate the efficacy of glenzocimab with EVT compared with EVT plus placebo, with or without intravenous thrombolysis (IVT), on functional outcome. Methods GREEN is a multicenter, randomized, double blind, placebo controlled study. Participants presenting with AIS and a large vessel occlusion of the anterior circulation (intracranial internal carotid artery or middle cerebral artery, or both), with symptoms onset within 24 hours, will be randomized to one of two groups: intravenous glenzocimab 1000 mg with standard of care (SoC-EVT±IVT) or SoC (EVT±IVT) plus placebo. The main primary efficacy endpoint is functional outcome (assessed by the modified Rankin Scale score) at 90 days. Conclusion This is the first randomized trial evaluating the efficacy of glenzocimab with EVT. This prospective trial aims to determine whether glenzocimab with EVT improves functional outcome. Trial registration ClinicalTrials.gov NCT05559398
- 1 August 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (8) , 2091-2100
Delay in Carotid Web Diagnosis Remains Common and Associated With an Increased Risk of Stroke Recurrence
BACKGROUND: Carotid web is a rare and likely underrecognized cause of ischemic stroke, particularly in young patients. Given the high risk of recurrence, diagnostic delays may have serious consequences. This study aimed to assess the incidence and impact of delayed carotid web diagnosis after a first ischemic event. METHODS: We conducted a retrospective analysis using data from the French ongoing multicenter prospective CAROWEB (Carotid Web registry). We included patients with a first-ever ischemic stroke or transient ischemic attack in the anterior circulation, attributed to an ipsilateral carotid web with no other identifiable cause, between September 2013 and April 2023. Patients with missing data on the date of the first ischemic event or carotid web diagnosis, or with prior stroke history, were excluded. Participants were categorized into early diagnosis (≤30 days) and delayed diagnosis (>30 days) groups. Factors associated with diagnostic delay were investigated through univariable and multivariable analyses. Stroke recurrence was evaluated using Kaplan-Meier survival analysis. RESULTS: Of 280 patients in the registry, 225 met the inclusion criteria. A delayed diagnosis occurred in 57 patients (25.3%). Independent predictors of diagnostic delay included lower initial National Institutes of Health Stroke Scale score (odds ratio, 0.92; P =0.002), stroke occurring before 2019 (odds ratio, 0.19; P P P =0.014). CONCLUSIONS: Delayed carotid web diagnosis remains common, especially in minor strokes, in the absence of early computed tomography angiography, and in events before 2019. Such delays are associated with a significantly increased risk of stroke recurrence, highlighting the need for early vascular imaging in ischemic stroke evaluation. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04431609.
- 1 August 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (8) , 2091-2100
Delay in Carotid Web Diagnosis Remains Common and Associated With an Increased Risk of Stroke Recurrence
BACKGROUND: Carotid web is a rare and likely underrecognized cause of ischemic stroke, particularly in young patients. Given the high risk of recurrence, diagnostic delays may have serious consequences. This study aimed to assess the incidence and impact of delayed carotid web diagnosis after a first ischemic event. METHODS: We conducted a retrospective analysis using data from the French ongoing multicenter prospective CAROWEB (Carotid Web registry). We included patients with a first-ever ischemic stroke or transient ischemic attack in the anterior circulation, attributed to an ipsilateral carotid web with no other identifiable cause, between September 2013 and April 2023. Patients with missing data on the date of the first ischemic event or carotid web diagnosis, or with prior stroke history, were excluded. Participants were categorized into early diagnosis (≤30 days) and delayed diagnosis (>30 days) groups. Factors associated with diagnostic delay were investigated through univariable and multivariable analyses. Stroke recurrence was evaluated using Kaplan-Meier survival analysis. RESULTS: Of 280 patients in the registry, 225 met the inclusion criteria. A delayed diagnosis occurred in 57 patients (25.3%). Independent predictors of diagnostic delay included lower initial National Institutes of Health Stroke Scale score (odds ratio, 0.92; P =0.002), stroke occurring before 2019 (odds ratio, 0.19; P P P =0.014). CONCLUSIONS: Delayed carotid web diagnosis remains common, especially in minor strokes, in the absence of early computed tomography angiography, and in events before 2019. Such delays are associated with a significantly increased risk of stroke recurrence, highlighting the need for early vascular imaging in ischemic stroke evaluation. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04431609.